Posts by: Ana Pena, PhD

Ana Pena, PhD

Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.

December 14, 2018

Stanford Pursues New Research to Understand Spread and Resistance of Aggressive Ovarian Cancer

News

A team led by researchers at Stanford University will test an approach combining new materials and imaging technologies to provide a deeper understanding of how high-grade serous ovarian cancer develops. The condition is ... Read more

September 7, 2018

Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows

News

Adding sorafenib, an anti-cancer oral medicine, to Hycamtin (topotecan) chemotherapy slows the time to disease progression or death in women with platinum-resistant ovarian cancer, a Phase 2 trial shows. The ... Read more

September 5, 2018

Algorithm Predicts Response to Measles Virus Therapy in Ovarian, Other Cancers, Study Shows

News

Researchers at the Mayo Clinic developed an algorithm to predict the response of ovarian cancer patients to measles virus therapy, an investigational anti-cancer treatment being developed by the large U.S.-based medical ... Read more

June 27, 2018

Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment

News

Mirvetuximab soravtansine (IMGN853), an investigational antibody-drug conjugate, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of ovarian cancer patients, ImmunoGen, the therapy’s maker, announced. The ... Read more

June 22, 2018June 22, 2018

A Second Surgery Can Improve Survival for Women with Recurring Ovarian Cancer, Study Shows

News

Follow-up surgery to remove all traces of cancer can improve the survival of women whose ovarian cancer returned after initial surgery and chemotherapy, a Norwegian study shows. In the study, ... Read more

May 21, 2018

Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June

News

Apealea, a water-soluble formulation of the chemotherapy paclitaxel, is not inferior to the standard formulation, Taxol (cremophor- EL paclitaxel), and may even improve the survival of ovarian cancer patients who responded to platinum-based ... Read more

May 11, 2018

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

News

The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and ... Read more

May 9, 2018

Siamab’s ST1 Therapy Candidate Promising Against Chemoresistant Ovarian Cancer, Study Shows

News

Siamab Therapeutics‘ investigational antibody-drug conjugate ST1 has promising anti-tumor effects against chemotherapy-resistant ovarian cancer in cell and animal models, a study shows. The study, “Treatment of ovarian cancer by targeting the tumor stem cell-associated ... Read more

April 30, 2018

Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial

News

Zejula (niraparib) showed an ability to treat people with recurrent and heavily treated ovarian cancer, particularly those with mutations in DNA repairing genes, results of a Phase 2 trial show. Tesaro’s ... Read more

April 23, 2018

New Sensor Detects Ovarian Cancer in Noninvasive Manner in Mice, Study Shows

News

A new sensor, found capable of identifying ovarian cancer in a noninvasive way in mice, may have the potential to detect early-stage ovarian cancer in the future, and possibly monitor for ... Read more